Utah Medical Products Stock Net Asset
| UTMD Stock | USD 64.57 0.39 0.61% |
Utah Medical Products fundamentals help investors to digest information that contributes to Utah Medical's financial success or failures. It also enables traders to predict the movement of Utah Stock. The fundamental analysis module provides a way to measure Utah Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Utah Medical stock.
Utah | Net Asset |
Utah Medical Products Company Net Asset Analysis
Utah Medical's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Utah Medical Net Asset | 135.46 M |
Most of Utah Medical's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Utah Medical Products is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Utah Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Utah Medical is extremely important. It helps to project a fair market value of Utah Stock properly, considering its historical fundamentals such as Net Asset. Since Utah Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Utah Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Utah Medical's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Utah Total Assets
Total Assets |
|
Based on the recorded statements, Utah Medical Products has a Net Asset of 135.46 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Utah Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Utah Medical's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Utah Medical could also be used in its relative valuation, which is a method of valuing Utah Medical by comparing valuation metrics of similar companies.Utah Medical is currently under evaluation in net asset category among its peers.
Utah Medical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Utah Medical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Utah Medical's managers, analysts, and investors.Environmental | Governance | Social |
Utah Medical Institutional Holders
Institutional Holdings refers to the ownership stake in Utah Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Utah Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Utah Medical's value.| Shares | Jpmorgan Chase & Co | 2024-06-30 | 62.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 49.6 K | Minerva Advisors Llc | 2024-09-30 | 42.3 K | Acadian Asset Management Llc | 2024-06-30 | 41.4 K | Hotchkis & Wiley Capital Management Llc | 2024-06-30 | 39 K | Millennium Management Llc | 2024-06-30 | 39 K | Northern Trust Corp | 2024-09-30 | 35.1 K | Isthmus Partners Llc | 2024-09-30 | 32.1 K | Los Angeles Capital Management Llc | 2024-09-30 | 30.6 K | Fmr Inc | 2024-09-30 | 268.8 K | Renaissance Technologies Corp | 2024-09-30 | 230.6 K |
Utah Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0818 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 131.25 M | ||||
| Shares Outstanding | 3.39 M | ||||
| Shares Owned By Insiders | 6.89 % | ||||
| Shares Owned By Institutions | 73.55 % | ||||
| Number Of Shares Shorted | 56.8 K | ||||
| Price To Earning | 31.38 X | ||||
| Price To Book | 1.77 X | ||||
| Price To Sales | 4.94 X | ||||
| Revenue | 50.22 M | ||||
| Gross Profit | 32.2 M | ||||
| EBITDA | 24.8 M | ||||
| Net Income | 16.64 M | ||||
| Cash And Equivalents | 69.51 M | ||||
| Cash Per Share | 19.17 X | ||||
| Total Debt | 342 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 13.44 X | ||||
| Book Value Per Share | 36.10 X | ||||
| Cash Flow From Operations | 22.28 M | ||||
| Short Ratio | 2.62 X | ||||
| Earnings Per Share | 4.28 X | ||||
| Number Of Employees | 169 | ||||
| Beta | 0.08 | ||||
| Market Capitalization | 217.67 M | ||||
| Total Asset | 135.46 M | ||||
| Retained Earnings | 138.34 M | ||||
| Working Capital | 101.56 M | ||||
| Current Asset | 32.87 M | ||||
| Current Liabilities | 4.07 M | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 1.20 % | ||||
| Net Asset | 135.46 M | ||||
| Last Dividend Paid | 1.2 |
About Utah Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Utah Medical Products's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Utah Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Utah Medical Products based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Utah Medical Products is a strong investment it is important to analyze Utah Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Utah Medical's future performance. For an informed investment choice regarding Utah Stock, refer to the following important reports:Check out Utah Medical Piotroski F Score and Utah Medical Altman Z Score analysis. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Utah Medical. If investors know Utah will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Utah Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 1.2 | Earnings Share 4.28 | Revenue Per Share 12.392 | Quarterly Revenue Growth (0.20) |
The market value of Utah Medical Products is measured differently than its book value, which is the value of Utah that is recorded on the company's balance sheet. Investors also form their own opinion of Utah Medical's value that differs from its market value or its book value, called intrinsic value, which is Utah Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Utah Medical's market value can be influenced by many factors that don't directly affect Utah Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Utah Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Utah Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Utah Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.